| Primary |
| Bronchitis |
21.4% |
| Ill-defined Disorder |
13.3% |
| Drug Use For Unknown Indication |
9.2% |
| Atrial Fibrillation |
8.2% |
| Hypertension |
6.1% |
| Ovulation Induction |
6.1% |
| Sinusitis |
4.1% |
| Urinary Tract Infection |
4.1% |
| Gastritis |
3.1% |
| Perinephric Abscess |
3.1% |
| Pyrexia |
3.1% |
| Acute Sinusitis |
2.0% |
| Bronchiolitis |
2.0% |
| Conjunctivitis |
2.0% |
| Dyspnoea |
2.0% |
| Febrile Infection |
2.0% |
| Lung Disorder |
2.0% |
| Otitis Media Acute |
2.0% |
| Pain |
2.0% |
| Respiratory Tract Infection |
2.0% |
|
| International Normalised Ratio Increased |
11.1% |
| Clostridium Difficile Colitis |
7.4% |
| Pancreatitis Acute |
7.4% |
| Pyrexia |
7.4% |
| Systemic Lupus Erythematosus |
7.4% |
| Tremor |
7.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.7% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
3.7% |
| Ear Haemorrhage |
3.7% |
| Gamma-glutamyltransferase Increased |
3.7% |
| Grand Mal Convulsion |
3.7% |
| Liver Injury |
3.7% |
| Melaena |
3.7% |
| Mucous Stools |
3.7% |
| Nephrotic Syndrome |
3.7% |
| Overdose |
3.7% |
| Purpura |
3.7% |
| Rash Erythematous |
3.7% |
| Rash Pustular |
3.7% |
| Renal Tubular Necrosis |
3.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
29.4% |
| Pyrexia |
7.4% |
| Bronchitis |
6.9% |
| Sinusitis |
6.4% |
| Product Used For Unknown Indication |
5.9% |
| Multiple Myeloma |
5.4% |
| Lymphoma |
4.9% |
| Renal Colic |
4.9% |
| Lobar Pneumonia |
3.9% |
| Nasopharyngitis |
3.4% |
| Tonsillitis |
3.4% |
| Diffuse Large B-cell Lymphoma |
2.5% |
| Hypertension |
2.5% |
| Acute Sinusitis |
2.0% |
| Bone Pain |
2.0% |
| Febrile Bone Marrow Aplasia |
2.0% |
| Ovulation Induction |
2.0% |
| T-cell Type Acute Leukaemia |
2.0% |
| Tooth Disorder |
2.0% |
| Gastritis |
1.5% |
|
| Intra-uterine Death |
14.3% |
| Stillbirth |
12.2% |
| Orthostatic Hypotension |
8.2% |
| Thrombotic Thrombocytopenic Purpura |
8.2% |
| Clostridium Difficile Colitis |
6.1% |
| Hepatitis |
6.1% |
| Mania |
4.1% |
| Pseudomembranous Colitis |
4.1% |
| Pyrexia |
4.1% |
| Rash Pustular |
4.1% |
| Systemic Lupus Erythematosus |
4.1% |
| Toxic Skin Eruption |
4.1% |
| Urticaria |
4.1% |
| Weight Decreased |
4.1% |
| Agranulocytosis |
2.0% |
| Anosmia |
2.0% |
| Colitis Ischaemic |
2.0% |
| Diarrhoea |
2.0% |
| Drug Exposure During Pregnancy |
2.0% |
| Drug Interaction |
2.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
26.0% |
| Pneumonia |
10.7% |
| Ear Infection |
5.3% |
| Premedication |
4.7% |
| Prophylaxis |
4.7% |
| Pyrexia |
4.7% |
| Sinusitis |
4.1% |
| Urinary Tract Infection |
4.1% |
| Asthma |
3.6% |
| Epilepsy |
3.6% |
| Her-2 Positive Breast Cancer |
3.6% |
| Influenza |
3.6% |
| Osteoporosis |
3.6% |
| Bronchitis |
3.0% |
| Product Used For Unknown Indication |
3.0% |
| Acth Decreased |
2.4% |
| Acute Sinusitis |
2.4% |
| Antibiotic Prophylaxis |
2.4% |
| Neuralgia |
2.4% |
| Neuritis |
2.4% |
|
| Tendonitis |
15.2% |
| Clostridium Difficile Colitis |
6.1% |
| Lung Disorder |
6.1% |
| Rash |
6.1% |
| Sputum Purulent |
6.1% |
| Stevens-johnson Syndrome |
6.1% |
| Toxic Skin Eruption |
6.1% |
| Tremor |
6.1% |
| Urticaria |
6.1% |
| Visual Field Defect |
6.1% |
| Cardiac Arrest |
3.0% |
| Coma |
3.0% |
| Drug Exposure During Pregnancy |
3.0% |
| Gamma-glutamyltransferase Increased |
3.0% |
| Gingival Bleeding |
3.0% |
| Haematemesis |
3.0% |
| Hemiplegia |
3.0% |
| Hepatic Enzyme Increased |
3.0% |
| Hypoglycaemic Coma |
3.0% |
| Hypothermia |
3.0% |
|
| Interacting |
| Hypertension |
21.2% |
| Helicobacter Infection |
18.2% |
| Pneumonia |
12.1% |
| Product Used For Unknown Indication |
7.6% |
| Aortic Valve Replacement |
6.1% |
| Cardiac Failure Chronic |
6.1% |
| Chronic Obstructive Pulmonary Disease |
6.1% |
| Hyperlipidaemia |
6.1% |
| Tachyarrhythmia |
6.1% |
| Atrial Fibrillation |
4.5% |
| Bronchitis |
3.0% |
| Arrhythmia Supraventricular |
1.5% |
| Hypercholesterolaemia |
1.5% |
|
| Drug Interaction |
57.1% |
| International Normalised Ratio Increased |
28.6% |
| Weight Decreased |
14.3% |
|
